Good morning. As AI becomes more widely used in health care, could it actually lead doctors to lose some of their skills? One ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

The Brennan family will host the 7th Annual Dance for Dravet on September 26th at the Third Degree Glass Factory to raise ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Dravet syndrome is a type of epilepsy that starts during a child's first year. If your child has this condition, they might have seizures that last for several minutes at a time.

People with Dravet syndrome experience intractable seizures throughout their lives — seizures that usually begin before they are 1 year old. What’s more, these seizures aren’t all of the ...

Dravet syndrome is a rare, severe form of epilepsy with symptoms that begin before a child turns 15 months old (and often within the first year of life). (1) Formerly known as severe myoclonic ...

As heatwaves become more intense with climate change, scientists are racing to understand how extreme heat changes the way ...